PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's environmental, social, and governance practices.
61.55
ESG score near Biotechnology median of 61.33. David Dodd would investigate if industry-standard ESG practices adequately address sector-specific risks.
53.79
Environmental score near Biotechnology median of 56.56. David Dodd would investigate if industry-standard environmental practices adequately address climate risks.
66.06
Social score near Biotechnology median of 64.69. David Dodd would investigate if industry-standard social practices adequately address stakeholder risks.
64.79
Governance score near Biotechnology median of 62.61. David Dodd would investigate if industry-standard governance adequately protects shareholder interests.